Inside xDRIVE: What Functional Precision Medicine Could Mean for CRC Patients
Choosing the right treatment for colorectal cancer can be overwhelming, especially when patients and providers don’t have clear guidance on which therapies may work best for an individual.
First Ascent Biomedical’s xDRIVE platform is a functional precision medicine approach that tests a patient’s own live tumor cells against hundreds of FDA-approved drugs — helping identify options based on how the cancer actually responds.
This clinical study — funded by Fight Colorectal Cancer (Fight CRC) — represents a collaborative effort to advance personalized treatment tools for CRC patients. You can read more about the partnership in the joint press release:
First Ascent Biomedical and Fight Colorectal Cancer Foundation Announce Groundbreaking Study
https://firstascentbiomedical.com/first-ascent-biomedical-and-fight-colorectal-cancer-foundation-an…
In this webinar, Fight CRC sits down with leaders from First Ascent Biomedical (Jim Foote, CEO and Co-Founder, and Diana Jenner, Head of Patient Advocacy) and a Fight CRC Research Advocate (Matthew DeAngelis, Stage IV Colorectal Cancer Survivor) to discuss the science behind xDRIVE, the ongoing clinical trial (NCT06929338), and what this emerging approach may mean for patients making complex treatment decisions.
This session explores:
- How functional precision medicine works and how xDRIVE differs from genomic-only testing
- What the xDRIVE clinical trial is measuring, and what participation looks like
- Advocate perspectives on the urgent need for predictive, patient-specific data
- How patients and families can stay informed about evolving treatment tools
Watch the webinar for an inside look at this innovative study and its potential to support more personalized care in colorectal cancer.
Fight CRC independently develops and curates all content.